Treatment of advanced melanoma: Past, present and future

Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.

Original languageEnglish
Article number208
Pages (from-to)1-15
Number of pages15
Issue number9
Publication statusPublished - 2020 Sep


  • BRAF inhibitors
  • Combination therapy
  • Immune checkpoints inhibitors
  • MEK inhibitors
  • Metastatic melanoma

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Biochemistry, Genetics and Molecular Biology(all)
  • Space and Planetary Science
  • Palaeontology

Fingerprint Dive into the research topics of 'Treatment of advanced melanoma: Past, present and future'. Together they form a unique fingerprint.

Cite this